

P Richard Harrigan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8440844/p-richard-harrigan-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

1,577
citations

20
h-index

39
g-index

47
ext. papers

1,892
ext. citations

6.4
avg, IF

3.98
L-index

#	Paper	IF	Citations
43	Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs. <i>Scientific Reports</i> , 2021 , 11, 9986	4.9	1
42	Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
41	Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus" Symposium. <i>Viruses</i> , 2020 , 12,	6.2	6
40	Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework. <i>Viruses</i> , 2020 , 12,	6.2	2
39	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. <i>Viruses</i> , 2020 , 12,	6.2	10
38	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. <i>Scientific Reports</i> , 2020 , 10, 1634	4.9	21
37	HIV-1 phylodynamic analysis among people who inject drugs in Pakistan correlates with trends in illicit opioid trade. <i>PLoS ONE</i> , 2020 , 15, e0237560	3.7	2
36	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 170-182	5.1	17
35	Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019 , 24, 211-220	1.6	0
34	Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz060	1	5
33	Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection. <i>Aging Cell</i> , 2019 , 18, e13018	9.9	16
32	A systematic review of the genetic mechanisms of dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3135-3149	5.1	41
31	Phylogenetic surveillance of travel-related Zika virus infections through whole-genome sequencing methods. <i>Scientific Reports</i> , 2019 , 9, 16433	4.9	1
30	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. <i>Infection, Genetics and Evolution</i> , 2019 , 69, 76-84	4.5	5
29	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. <i>Journal of Virology</i> , 2019 , 93,	6.6	11
28	Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013. <i>AIDS Patient Care and STDs</i> , 2018 , 32, 257-264	5.8	8
27	Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. <i>Antiviral Research</i> , 2018 , 159, 45-54	10.8	6

26	Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25193	5.4	24
25	Phylogenetic approach to recover integration dates of latent HIV sequences within-host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E8958-E8967	11.5	23
24	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study. <i>Lancet HIV,the</i> , 2017 , 4, e303-e310	7.8	24
23	Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. <i>PLoS ONE</i> , 2017 , 12, e0184848	3.7	4
22	Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion. <i>Aging</i> , 2017 , 9, 687-705	5.6	22
21	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. <i>Journal of Virology</i> , 2016 , 90, 1244-58	6.6	9
20	Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative. <i>Clinical Infectious Diseases</i> , 2016 , 62, 640-7	11.6	30
19	The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 698-702	25.5	35
18	Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. <i>Journal of Hepatology</i> , 2016 , 64, 1247-55	13.4	18
17	Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. <i>Lancet HIV,the</i> , 2016 , 3, e231-8	7.8	122
16	The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2015 , 211, 926-35	7	73
15	Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1288-95	7	42
14	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort. <i>International Journal of Epidemiology</i> , 2015 , 44, 58-67	7.8	27
13	Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3585-98	5.9	78
12	Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1012-9	11.6	66
11	"Deep" sequencing accuracy and reproducibility using Roche/454 technology for inferring co-receptor usage in HIV-1. <i>PLoS ONE</i> , 2014 , 9, e99508	3.7	9
10	GWATCH: a web platform for automated gene association discovery analysis. <i>GigaScience</i> , 2014 , 3, 18	7.6	2
9	Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. <i>PLoS Genetics</i> , 2014 , 10, e1004295	6	34

8	Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing. <i>Nucleic Acids Research</i> , 2014 , 42, e98	20.1	27
7	Temporal trends in the discontinuation of first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2202-9	5.1	19
6	Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. <i>PLoS ONE</i> , 2014 , 9, e87872	3.7	226
5	Blood mitochondrial DNA mutations in HIV-infected women and their infants exposed to HAART during pregnancy. <i>Aids</i> , 2012 , 26, 675-83	3.5	15
4	Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates. <i>Antiviral Therapy</i> , 2007 , 12, 1097-1106	1.6	88
3	HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1325-30	7	38
2	Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2005 , 191, 339-47	7	349
1	Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. <i>Antiviral Therapy</i> , 2003 , 8, 91-96	1.6	12